Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,21€(+68,40%). Der Median liegt bei 4,21€(+68,40%).
Kaufen | 5 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco, CA. Presentation Details: Title: Cytisinicline Reduces Cravings and Nicotine Intake in People Who Smoke and Don't Quit Completely Session: C95 – Public Health and Policy Relevant Research Format: Mini Symposium Oral Presentation Date & Time: Tuesday, May 20, 2025; 2:15 PM – 4:15 PM EDT Location: 2025 ATS International Conference The oral presentation will highlight the unique benefit of cytisinicline treatment in clinical trials in reducing nicotine cravings which led to reduced nicotine intake, even in individuals who did not achieve complete smoking cessation.» Mehr auf globenewswire.com
Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Nicole Jones - Investor Relations Rick Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Mark Oki - Chief Financial Officer Jaime Xinos - Chief Commercial Officer Conference Call Participants Gary Nachman - Raymond James Justin Walsh - Jones Trading John Vandermosten - Zacks Investment Research Operator Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings Conference Call and Webcast.» Mehr auf seekingalpha.com
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. “The Achieve team is fully committed to finalizing the NDA for submission to the FDA next month.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −11,86 Mio | 97,05% |
EBITDA | 0,00 | 100,00% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 96,54 Mio€ |
Anzahl Aktien | 34,69 Mio |
52 Wochen-Hoch/Tief | 4,95€ - 1,63€ |
Dividenden | Nein |
Beta | 1,5 |
KGV (PE Ratio) | −2,36 |
KGWV (PEG Ratio) | 0,27 |
KBV (PB Ratio) | 10,60 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Achieve Life Sciences, Inc. ist ein pharmazeutisches Unternehmen im klinischen Stadium, das Cytisiniclin für die Raucherentwöhnung und Nikotinsucht in Kanada, den Vereinigten Staaten und Großbritannien entwickelt und vermarktet. Das Unternehmen bietet Cytisinicline an, ein pflanzliches Alkaloid, das mit Nikotinrezeptoren im Gehirn interagiert und so die Schwere der Nikotinentzugssymptome verringert. Es hat Lizenzvereinbarungen mit Sopharma AD und der Universität von Bristol. Das Unternehmen hat seinen Sitz in Vancouver, Kanada.
Name | Achieve Life Sciences |
CEO | Dr. Richard A. B. Stewart |
Sitz | Vancouver, bc USA |
Website | |
Industrie | Gesundheitswesen: Ausstattung und Produkte |
Börsengang | |
Mitarbeiter | 25 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ACHV |
Frankfurt | SP4P.F |
Düsseldorf | SP4P.DU |
München | SP4P.MU |
Assets entdecken
Shareholder von Achieve Life Sciences investieren auch in folgende Assets